Trial Profile

A Biomarker Study in Men With Localized, Favorable, Intermediate-risk Prostate Cancer Treated With Aglatimagene Besadenovec

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aglatimagene besadenovec (Primary) ; Aglatimagene besadenovec (Primary) ; Valaciclovir (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Pharmacokinetics
Sponsors Candel Therapeutics

19 Feb 2026 Number of treatment arms are increased from 1 to 2 by the addition of Active Comparator: Control arm. Study design is changed from Single Group Assignment to parallel. "Biomarker" primary end-points are removed and only "Biodistribution of aglatimagene besadenovec" is retained. Thus the primary focus of this study now is the PK of stydt drug.
19 Feb 2026 Planned number of patients changed from 30 to 45.
19 Feb 2026 Planned End Date changed from 1 Jun 2026 to 1 Aug 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com